Skip to main content
U.S. flag

An official website of the United States government

EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer's disease

Bibliographic

Year of Publication:
2007
Contact PI Name:
Yuan Luo
Contact PI Affiliation:
Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, USA
Co-Authors:
Flaubert Tchantchou, Yanan Xu, Yanjue Wu, Yves Christen
Primary Reference (PubMED ID):
Funding Source:
Ipsen Pharma France
National Institutes of Health (NIH)
National Center for Complementary and Alternative Medicine (NCCAM)
Study Goal and Principal Findings:

Standardized Ginkgo biloba extract EGb 761 exhibits beneficial effects to patients with Alzheimer's disease (AD). It was previously demonstrated that EGb 761 inhibits amyloid beta (Abeta) oligomerization in vitro, protects neuronal cells against Abeta toxicity, and improves cognitive defects in a mouse model of AD (Tg 2576). In this study, the neurogenic potential of EGb 761 and its effect on cAMP response element binding protein (CREB) were examined in a double transgenic mouse model (TgAPP/PS1). EGb 761 significantly increases cell proliferation in the hippocampus of both young (6 months) and old (22 months) TgAPP/PS1 mice, and the total number of neuronal precursor cells in vitro in a dose-dependent manner. Furthermore, Abeta oligomers inhibit phosphorylation of CREB and cell proliferation in the hippocampus of TgAPP/PS1 mice. Administration of EGb 761 reduces Abeta oligomers and restores CREB phosphorylation in the hippocampus of these mice. The present findings suggest that 1) enhanced neurogenesis by EGb 761 may be mediated by activation of CREB, 2) stimulation of neurogenesis by EGb 761 may contribute to its beneficial effects in AD patients and improved cognitive functions in the mouse model of AD, and 3) EGb 761 has therapeutic potential for the prevention and improved treatment of AD.

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Natural Product
Therapeutic Agent:
Ginkgo Biloba Extract (EGb761)
Therapeutic Target:
Multi Target

Animal Model

Model Information:
Species:
Mouse
Model Type:
APPxPS1
Strain/Genetic Background:
C57BL/6J

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest

Outcomes

Outcome Measured
Outcome Parameters
Biochemical
CREB/phospho-CREB
Brain-beta Amyloid Peptide-Total
Neural Cell Adhesion Molecule 180 (NCAM180)
Immunochemistry
Neurogenesis
Cell Differentiation
Glial Fibrillary Acidic Protein (GFAP)
Neuronal Marker NeuN
Brain-beta Amyloid Oligomers
Brain-beta Amyloid Deposits
phospho-cAMP Response Element-Binding Protein (phospho-CREB)
Cell Proliferation
Cell Biology
Cell Proliferation
Neurogenesis